Clinical imaging in anti-atherosclerosis drug development
| Autor: | Heiko G. Niessen, Jörg Kreuzer, Alexander Ehlgen, Anders Bylock, Florian Gantner, Michael Koslowski |
|---|---|
| Rok vydání: | 2015 |
| Předmět: |
Diagnostic Imaging
Pharmacology Clinical Trials as Topic medicine.medical_specialty medicine.diagnostic_test Endpoint Determination business.industry Ultrasound food and beverages Magnetic resonance imaging Biochemical biomarkers Atherosclerosis Plaque Atherosclerotic Drug development Positron emission tomography Drug Design Positron-Emission Tomography Drug Discovery Intravascular ultrasound Humans Medicine Radiology Anti atherosclerosis Clinical imaging business |
| Zdroj: | Drug Discovery Today. 20:1317-1327 |
| ISSN: | 1359-6446 |
| DOI: | 10.1016/j.drudis.2015.06.014 |
| Popis: | The development of novel drugs for the treatment of atherosclerosis faces many challenges, particularly caused by the need for large and costly outcome trials. When predictive biochemical biomarkers are not available, clinical imaging data can serve as intermediate Phase II endpoints to demonstrate mechanistic and anti-atherosclerotic activity of new compounds. These data can support risk mitigation before continuing development in large Phase III outcome trials. Imaging techniques such as magnetic resonance imaging (MRI), computed tomography (CT) and ultrasound [intima-media thickness (IMT) and intravascular ultrasound (IVUS)] can provide detailed information on vascular plaque volume and morphology, whereas functional changes can potentially be captured by positron emission tomography (PET) techniques in the vessel wall. We will review the application and operational aspects of clinical imaging methods and endpoints used in interventional atherosclerosis trials. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect